ES2531085T3 - Fracciones de permeado de suero de leche y su uso para la prevención y la terapia de diabetes de tipo 2 y de síndrome metabólico - Google Patents

Fracciones de permeado de suero de leche y su uso para la prevención y la terapia de diabetes de tipo 2 y de síndrome metabólico Download PDF

Info

Publication number
ES2531085T3
ES2531085T3 ES07788206T ES07788206T ES2531085T3 ES 2531085 T3 ES2531085 T3 ES 2531085T3 ES 07788206 T ES07788206 T ES 07788206T ES 07788206 T ES07788206 T ES 07788206T ES 2531085 T3 ES2531085 T3 ES 2531085T3
Authority
ES
Spain
Prior art keywords
diabetes
fractions
therapy
prevention
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07788206T
Other languages
English (en)
Inventor
Jobst Krauskopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUK Beteiligungs GmbH
S u K BETEILIGUNGS GmbH
Original Assignee
SUK Beteiligungs GmbH
S u K BETEILIGUNGS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUK Beteiligungs GmbH, S u K BETEILIGUNGS GmbH filed Critical SUK Beteiligungs GmbH
Application granted granted Critical
Publication of ES2531085T3 publication Critical patent/ES2531085T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Fracción aislada de permeado de suero de leche dulce que comprende uno o varios polipéptidos con una masa de 100 a 3500 Dalton, preferiblemente de 200 a 3000 Dalton.
ES07788206T 2006-08-03 2007-08-03 Fracciones de permeado de suero de leche y su uso para la prevención y la terapia de diabetes de tipo 2 y de síndrome metabólico Active ES2531085T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006036285A DE102006036285A1 (de) 2006-08-03 2006-08-03 Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms
PCT/EP2007/058073 WO2008015275A1 (de) 2006-08-03 2007-08-03 Fraktionen aus molkepermeat und deren verwendung zur prävention und therapie des typ-2 diabetes und des metabolischen syndroms

Publications (1)

Publication Number Publication Date
ES2531085T3 true ES2531085T3 (es) 2015-03-10

Family

ID=38670475

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07788206T Active ES2531085T3 (es) 2006-08-03 2007-08-03 Fracciones de permeado de suero de leche y su uso para la prevención y la terapia de diabetes de tipo 2 y de síndrome metabólico

Country Status (5)

Country Link
US (1) US9877995B2 (es)
EP (1) EP2048969B1 (es)
DE (1) DE102006036285A1 (es)
ES (1) ES2531085T3 (es)
WO (1) WO2008015275A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008341009B2 (en) * 2007-12-21 2011-05-19 Dairy Innovation Australia Pty Ltd Processing of dairy ingredients by ultra-sonication
ES2558828T3 (es) 2011-03-29 2016-02-09 Chr. Hansen A/S Inactivación de bacteriófagos en un líquido
WO2019091472A1 (zh) * 2017-11-13 2019-05-16 江苏大学 乳蛋白活性肽的超声辅助模拟消化方法及保健食品应用
CN108786766A (zh) * 2018-05-04 2018-11-13 浙江工业大学 一种基于衣康酸键合硅胶的亲水色谱固定相及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
DE2903558C2 (de) 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
JPS6263553A (ja) 1985-09-17 1987-03-20 Snow Brand Milk Prod Co Ltd Ｌ−カルニチンの調製方法
JPS6387944A (ja) 1986-10-02 1988-04-19 Chugai Pharmaceut Co Ltd 乳清ミネラルおよびその利用
US5213826A (en) * 1987-11-05 1993-05-25 Land O'lakes, Inc. Whey permeate-derived sweetener
US5654019A (en) * 1991-12-26 1997-08-05 Snow Brand Milk Products Co., Ltd. Bone enhancing factors from whey and compositions containing the same
IT1263004B (it) 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
GB9312369D0 (en) * 1993-06-16 1993-07-28 Sandoz Nutrition Ltd Organic compounds
US6096870A (en) * 1994-01-05 2000-08-01 Sepragen Corporation Sequential separation of whey
US5639501A (en) * 1995-01-31 1997-06-17 Vembu; Rajan Separation of minerals from whey permeate
US7094949B2 (en) * 1995-05-16 2006-08-22 A2 Corporation Limited Breeding and milking cows for milk free of β-casein A1
DE29623285U1 (de) 1996-10-25 1998-01-22 Privates Institut Bioserv GmbH, 18059 Rostock Geschmacksneutrale Mikrokapseln und diese enthaltende Lebens- oder Futtermittel
AUPP051497A0 (en) * 1997-11-24 1997-12-18 University Of Melbourne, The Antimicrobial peptides
FI104783B (fi) * 1998-02-12 2000-04-14 Valio Oy Herasuolajauhe, menetelmä sen valmistamiseksi ja sen käyttö
DE69920219T2 (de) * 1998-06-17 2005-09-22 New Zealand Dairy Board Bioaktive molke-eiweisshydrolysate
DE19854749A1 (de) 1998-11-27 2000-05-31 Privates Inst Bioserv Gmbh Verwendung von Kapseln, die eine oder mehrere antigene Substanzen enthalten, zur Prävention und/oder Behandlung von Autoimmunerkrankungen
EP1154760A1 (de) 1999-02-19 2001-11-21 Bioserv AG Bioabbaubare komposite zur herstellung von mikrokapseln
GB9927603D0 (en) 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
JP4701472B2 (ja) 2000-04-21 2011-06-15 雪印乳業株式会社 乳カルシウム組成物の製造方法
JP2002037738A (ja) 2000-07-25 2002-02-06 Kotobuki Chemical:Kk 脂肪前駆細胞から脂肪細胞への分化抑制剤とこの脂肪細胞への分化抑制剤に用いる活性化乳清及びその活性化乳清の製造方法。
US6592863B2 (en) * 2000-08-22 2003-07-15 Nestec S.A. Nutritional composition
US6465432B1 (en) * 2000-08-28 2002-10-15 Kraft Food Holdings, Inc. Isolated antioxidant peptides form casein and methods for preparing, isolating, and identifying antioxidant peptides
NZ507335A (en) * 2000-10-05 2004-10-29 New Zealand Dairy Board Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP
CA2426508A1 (en) * 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
CA2437081C (en) * 2000-12-07 2010-10-19 Dsm Ip Assets B.V. Protein hydrolysates enriched in peptides having a carboxy terminal proline residue
US7648721B2 (en) * 2001-07-18 2010-01-19 Dsm Ip Assets B.V. Hydrolyzed milk proteins
DE10135493A1 (de) 2001-07-20 2003-01-30 Jobst Krauskopf Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie
DE10135494A1 (de) 2001-07-20 2003-11-06 Jobst Krauskopf Verwendung eines Lactatsalzes zur Behandlung und Prophylaxe der Athereosklerose
US20030118662A1 (en) 2001-12-05 2003-06-26 Glanbia Foods, Inc. Therapeutic uses of milk mineral fortified food products
US20030166866A1 (en) * 2002-01-28 2003-09-04 Land O' Lakes, Inc. Method of processing a proteinaceous material to recover K-casein macropeptide and polymers of a-lactalbumin and B-lactoglobulin
GB0213612D0 (en) 2002-06-13 2002-07-24 Novartis Nutrition Ag Organic compounds
FR2841473B1 (fr) * 2002-06-27 2004-09-17 Ingredia Utilisation d'au moins un peptide de la caseine s2 a activite inhbitrice de l'enzyme de conversion de l'engiotensine i pour la preparation de medicaments, d'aliments et de complements alimentaires
DE10233229A1 (de) 2002-07-22 2004-02-12 S.K. Enterprise Gmbh Pharmazeutische Zusammensetzung zur Senkung des Triglyceridspiegels
US20040162414A1 (en) * 2002-11-22 2004-08-19 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
US20060171992A1 (en) 2002-12-20 2006-08-03 Gerhardt Cinderella C Blood glucose regulating composition
ATE397453T1 (de) 2003-06-30 2008-06-15 Nestec Sa Zusammensetzung zur behandlung und/oder vorbeugung von insulinresistenz
DE10331202A1 (de) 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
WO2005058344A1 (en) * 2003-12-19 2005-06-30 The University Of Melbourne Antimicrobial composition
US7799363B2 (en) * 2004-10-07 2010-09-21 Next Proteins, Inc. Protein beverage and protein beverage concentrate and methods of making the same
JP2008519988A (ja) * 2004-11-12 2008-06-12 ファイザー・インク アミロイド−ベータペプチドを測定する方法
ES2319475B1 (es) * 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
WO2007004876A2 (en) * 2005-06-30 2007-01-11 Campina Nederland Holding B.V. Peptides inhibiting angiotensin-converting enzyme
RU2304167C2 (ru) * 2005-09-15 2007-08-10 Общество с ограниченной ответственностью "МЕДБИОФАРМ-БИОТЕХ" Способ получения гликопептидов и гликопептидный продукт, полученный этим способом, для использования в медицине
US20070092632A1 (en) * 2005-10-21 2007-04-26 Stan Kubow Ultra high pressure modified proteins and uses thereof
US20070116802A1 (en) * 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
ES2529237T3 (es) * 2006-12-20 2015-02-18 Dupont Nutrition Biosciences Aps Hidrolizados de proteínas de la leche con potencial inmunogénico reducido

Also Published As

Publication number Publication date
US9877995B2 (en) 2018-01-30
DE102006036285A1 (de) 2008-02-07
EP2048969A1 (de) 2009-04-22
EP2048969B1 (de) 2014-12-10
US20090274768A1 (en) 2009-11-05
WO2008015275A1 (de) 2008-02-07

Similar Documents

Publication Publication Date Title
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
EA201001628A1 (ru) Модифицированные полипептиды фактора vii и их применение
BRPI0716495A2 (pt) (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos.
EP2657333A4 (en) PIG CIRCOVIRUS OF TYPE 2, IMMUNA COMPOSITION THEREOF, TESTKIT AND USE THEREOF
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
IL192631A (en) A drug containing an isolated antibody or a functional portion thereof, pharmaceutical preparations and a kit containing it
IL197831A (en) Human antibodies that bind 4cxcr, preparations containing them and their uses
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
BRPI0918139A2 (pt) composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
CL2008000008A1 (es) Uso de un antigeno de circovirus porcino de tipo 2 (pcv2) para la profilaxis y tratamiento del complejo respiratorio porcino (prdc) y/o cualquier signo clinico asociado con prdc en un animal.
BRPI0719250A2 (pt) Métodos e composições com opalescência reduzida.
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
SV2008002906A (es) Metodos y composiciones para modular la hemostasiaref. cho.0267b-sv
CL2008003546A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii.
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
BRPI0814931A2 (pt) Composto com atividade contra hcv, sua composição e seu uso
CL2008000303A1 (es) Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion.
BRPI0812766A2 (pt) 4-cloro-4-alcóxi-1,1,1-triflúor-2-butanonas, preparação das mesmas e uso das mesmas no preparo de 4-alcóxi-1,1,1-triflúor-3-buten-2-onas
FR2900332B1 (fr) Composition dentaire en deux parties.
NO2020041I1 (no) Indakaterolacetat eller indakaterolxinafoat i kombinasjon med mometasonfuroat, fortrinnsvis indakaterolacetat i kombinasjon med mometasonfuroat
DK2160202T3 (da) Sammensætninger som emmiterer positroner og indeholder uorganiske partikler, og anvendelse deraf i medicin, især ved diagnostiske processer